Vitiligo

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

New data from a study on adult vitiligo patients indicates that both autoimmune/autoinflammatory and non-autoimmune comorbidities have higher occurrence rates for vitiligo patients.

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

New research demonstrated that 5-fluorouracil and microneedling in conjunction showed stronger results for the 19 participants than tacrolimus monotherapy as a treatment for vitiligo.

New data suggests occupational exposure to certain melanocytotoxic chemicals may lead to vitiligo.

Dr. Raj Chovatiya shares his thoughts on the recent approval of ruxolitinib for treatment of vitiligo and where he might use it, either alone or in combination with other vitiligo treatments.

Iltefat Hamzavi, MD, explores key areas of patient communication that may shape adherence and outcomes in patients with vitiligo.

Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.

Pearl E. Grimes, MD, discusses intervention strategies for vitiligo, including stabilization, repigmentation, and maintenance. She also explores factors that impact therapeutic outcomes.

John E. Harris, MD, PhD, reviews factors that shape prevalence of vitiligo and also explores the impact of vitiligo on patient quality of life.

In a recent study, DAMPs were found to play a major role in deteriorating vitiligo conditions by initiating host defenses against signals of danger.

Why patience is key following the major FDA decision earlier this year.

An interview with Dr. Rosen regarding his SDPA 2022 presentation on dermatologic conditions with white spots that are often misdiagnosed as vitiligo.

A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests the use of simvastatin treatment may be helpful for patients with nonsegmental vitiligo and dyslipidemia.

A new population-based study demonstrates an association between patients having systemic sclerosis and vitiligo, suggesting both conditions may need to be monitored for comorbidities.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

Only 7% of trials included a patient-reported outcome measure as a primary outcome measure.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.

A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.

A 1-unit increase in mean weekly SPD scores was linked to a 1.4-times increase in clinic visits for itch among adults aged 65 years or old.